Key result
Targeted TKIs show activity against TPM3 fusion-driven cancers, though acquired resistance limits long-term efficacy.
Why the study?
Beyond its role in muscle physiology, TPM3 is implicated in oncogenesis, prompting a review to elucidate the molecular mechanisms, tumor types, and clinical implications of TPM3 gene fusions.
Do tyrosine kinase inhibitors provide therapeutic benefit for tumors driven by TPM3 gene fusions?
Do tyrosine kinase inhibitors provide therapeutic benefit for tumors driven by TPM3 gene fusions?
TPM3 fusions define a histology-agnostic molecular subset of cancers with actionable vulnerabilities to targeted tyrosine kinase inhibitors.
Answers are grounded in this paper and cite their sources.
May support TKI consideration in rare TPM3 fusion-positive tumors; leaves open optimal sequencing and resistance strategies.
BACKGROUND: Tropomyosin 3 (TPM3), one of the four tropomyosin genes, is predominantly expressed in eukaryotic cells. As a crucial regulatory protein, TPM3 associates with actin within thin myofilaments, thereby playing an essential role in the regulation of muscle contraction. Beyond its fundamental function in muscle physiology, TPM3 is implicated in oncogenesis. OBJECTIVE: This review elucidates the molecular mechanisms underpinning TPM3 gene fusions, delineates the tumor types associated with these fusions, and examines their clinical implications. FINDINGS: Gene fusions such as TPM3-NTRK1, TPM3-ALK, and TPM3-ROS1 have been identified as oncogenic drivers in various cancers. These fusions promote constitutive activation of tyrosine kinases, disrupt normal cellular signaling, and consequently accelerate tumorigenesis. Malignancies harboring TPM3 fusions encompass several tumor categories. With the advent of tyrosine kinase inhibitors (TKIs) targeting NTRK1, ALK, and ROS1 fusions, these rearrangements have gained significant therapeutic relevance. However, resistance mechanisms and tumor heterogeneity pose ongoing challenges to targeted therapy. CONCLUSION: By synthesizing current evidence, this review aims to provide insights into the diagnostic, prognostic, and therapeutic landscape of TPM3-related gene fusions, fostering advancements in precision oncology.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted a review in Various cancers with TPM3 gene fusions (e.g., colorectal cancer, non-small cell lung cancer, inflammatory myofibroblastic tumors, thyroid carcinomas). Tyrosine kinase inhibitors (e.g., larotrectinib, entrectinib, crizotinib) was evaluated. TPM3 gene fusions act as oncogenic drivers in multiple cancers and serve as actionable targets for tyrosine kinase inhibitors, though acquired resistance remains a clinical challenge.
Synapse has enriched 10 related papers. Consider them for comparative context: